June 1, 2026 U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
June 1, 2026 Meey Global Confidentially Submits Draft Registration Statement with the U.S. Securities and Exchange Commission
June 1, 2026 XRP/USD Holds Near $1.30 as Volatility Builds and Traders Turn to AI Bots Like AIX Alpha
